Abstract: An energy Internet system, an energy routing conversion device, and an energy control method, relating to a field of energy information. An alternating-current (AC) side energy routing conversion device of the energy Internet system includes a plurality of first route ports, and a direct-current (DC) side energy routing conversion device includes a plurality of second route ports, where each second route port is connected to a corresponding first route port by means of a corresponding DC busbar. A plurality of energy devices are connected to a DC busbar by means of corresponding first AC/DC converters or first DC converters. The AC side energy routing conversion device and the DC side energy routing conversion device collect energy information of the energy devices and adjust energy of the energy devices on a basis of energy balance constraint conditions.

Abstract: Disclosed herein are batteries and methods of making batteries. The batteries disclosed herein generally comprise a cathode, an electrolyte capable of conducting protons and/or hydronium ions, and an anode comprising a material capable of absorbing protons and/or hydronium ions, wherein (i) the cathode is in contact with a cathode substance, or (ii) the electrolyte comprises a reduced cathode substance, or (iii) the cathode is in contact with a cathode substance and the electrolyte comprises a reduced cathode substance, and wherein the cathode substance is an oxide of one or more metals or an oxide of a halide.

Abstract: The present invention provides an optical signal transmission system and method for rotary joints. The system comprises a hollow cylindrical rotor, a hollow cylindrical stator, a plurality of sets of photodetectors arranged on the inner cylindrical wall of the rotor and the stator respectively, a plurality of optical signal sources and optical signal transmit-receive channels. Light beams emitted from the optical signal sources reach the corresponding photodetectors through the optical signal transmit-receive channels. The corresponding photodetectors convert optical signals into electrical signals. Optical signals are transmitted in the optical signal transmission system for symmetric duplex communication, where there is no distinction between uplink and downlink.

Abstract: Disclosed herein are batteries and methods of making batteries. The batteries disclosed herein generally comprise a cathode, an electrolyte capable of conducting protons and/or hydronium ions, and an anode comprising a material capable of absorbing protons and/or hydronium ions, wherein (i) the cathode is in contact with a cathode substance, or (ii) the electrolyte comprises a reduced cathode substance, or (iii) the cathode is in contact with a cathode substance and the electrolyte comprises a reduced cathode substance, and wherein the cathode substance is an oxide of one or more metals or an oxide of a halide.

Abstract: A process for producing a purified extract comprising between about 40% and about 90% theaflavins is provided. Purified theaflavin extract produced by the disclosed process is provided which comprises less than about 5% TF1, between about 10% and about 60% TF2a, between about 5% and about 35% TF2b, and between about 10% and about 65% TF3. Individual dosage compositions are provided for the control of a physiological disorder comprising about 5% to about 95% theaflavins in a pharmaceutically acceptable vehicle or a dietary supplement vehicle. Further individual dosage compositions are provided which comprise an effective amount of substantially only one theaflavin species selected from the group consisting of TF1, TF2a, TF2b, and TF3. Individual dosage compositions are provided which comprise an effective amount of substantially only two theaflavin species selected from the group consisting of TF1 and TF2a, TF1 and TF2b, TF1 and TF3, TF2a and TF2b, TF2a and TF3, TF2b and TF3.

Abstract: A process for producing purified theaflavin extract is provided which comprises combining an organic solvent with tea leaves, extracting polyphenols from the tea leaves to produce an organic stock substrate solution; producing a second batch of tea leaves; grinding the second batch of tea leaves to produce stock fermentation enzyme; combining the stock substrate solution with the stock fermentation enzyme to produce a fermentation mixture; fermentation of the mixture to produce theaflavins; and, separating the theaflavins from the fermentation mixture to produce purified theaflavin extract. Oral dosage forms are provided which comprise an effective amount of the purified theaflavin extract. Methods of treatment of human physiological disorders are provided which comprise administering an oral dosage form.

Abstract: A process for producing purified theaflavin extract is provided which comprises combining an organic solvent with tea leaves, extracting polyphenols from the tea leaves to produce an organic stock substrate solution; producing a second batch of tea leaves; grinding the second batch of tea leaves to produce stock fermentation enzyme; combining the stock substrate solution with the stock fermentation enzyme to produce a fermentation mixture; fermentation of the mixture to produce theaflavins; and, separating the theaflavins from the fermentation mixture to produce purified theaflavin extract. Oral dosage forms are provided which comprise an effective amount of the purified theaflavin extract. Methods of treatment of human physiological disorders are provided which comprise administering an oral dosage form.

Abstract: A process for producing a purified extract comprising between about 40% and about 90% theaflavins is provided. Purified theaflavin extract produced by the disclosed process is provided which comprises less than about 5% TF1, between about 10% and about 60% TF2a, between about 5% and about 35% TF2b, and between about 10% and about 65% TF3. Individual dosage compositions are provided for the control of a physiological disorder comprising about 5% to about 95% theaflavins in a pharmaceutically acceptable vehicle or a dietary supplement vehicle. Further individual dosage compositions are provided which comprise an effective amount of substantially only one theaflavin species selected from the group consisting of TF1, TF2a, TF2b, and TF3. Individual dosage compositions are provided which comprise an effective amount of substantially only two theaflavin species selected from the group consisting of TF1 and TF2a, TF1 and TF2b, TF1 and TF3, TF2a and TF2b, TF2a and TF3, TF2b and TF3.